icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   6 Trials   6 Trials   4342 News 


«12...2324252627282930313233...5051»
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    $AMRN #ESC20 #vascepa (Twitter) -  Aug 29, 2020   
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Clinical, Journal:  Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. (Pubmed Central) -  Aug 27, 2020   
    This drug profile outlines the risks and benefits attributable to IPE and the patient population for whom treatment has now been proven to be effective in reducing CVD events.Areas Covered: Icosapent Ethyl (IPE) is a highly purified form of eicosapentanoic acid for patients with elevated triglycerides as monotherapy or combined with statins and/or other lipid lowering therapies.The REDUCE-IT Study demonstrated a 25% reduction in the primary outcome measure and 30% reduction in total CVD events in high risk patients with elevated triglycerides (135-499 mg/dL) assigned to IPE (4 grams daily).Side effects included a statistically increased risk of atrial fibrillation and bleeding, although the risk of stroke was reduced and there were no cases of fatal bleeding.The FDA recently approved IPE for treatment of patients with triglyceride levels of 150-499 mg/dL and pre-existing CVD or Type 2 diabetes mellitus with 2 or more risk factors.Expert opinion:IPE has proven to be superior to other forms of OM3FA in reducing CVD risk in patients with elevated TG. This could be attributed to multiple factors including the use of highly purified EPA ethyl esters without DHA, thus preventing the increase in LDL-C associated with DHA especially at high TG levels, reduction in atherogenic TG-rich particles, antioxidant and anti-inflammatory properties, improvement in endothelial function and stabilization of atherosclerotic plaque.
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Vascepa? @DLBHATTMD (Twitter) -  Aug 23, 2020   
  • ||||||||||  icosapent ethyl / Generic mfg.
    Clinical, Journal:  REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States. (Pubmed Central) -  Aug 13, 2020   
    P3
    While the non-USA subgroup showed significant reductions in the primary and key secondary endpoints, the USA subgroup demonstrated particularly robust risk reductions across a variety of composite and individual endpoints, including all-cause mortality. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.